vs
Apellis Pharmaceuticals, Inc.（APLS）与SAFETY INSURANCE GROUP INC（SAFT）财务数据对比。点击上方公司名可切换其他公司
SAFETY INSURANCE GROUP INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$319.3M vs $199.9M），SAFETY INSURANCE GROUP INC净利率更高（6.3% vs -29.5%，领先35.8%），SAFETY INSURANCE GROUP INC同比增速更快（11.4% vs -5.9%），SAFETY INSURANCE GROUP INC自由现金流更多（$192.0M vs $-14.3M），过去两年SAFETY INSURANCE GROUP INC的营收复合增速更高（9.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
全美互助保险集团及其关联公司，常简称为Nationwide，是一家总部位于美国俄亥俄州哥伦布市的大型保险金融服务集团，在亚利桑那州斯科茨代尔、爱荷华州得梅因都设有区域总部。目前集团拥有约2.4万名员工，位列2025年财富美国500强榜单第72名。
APLS vs SAFT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $319.3M |
| 净利润 | $-59.0M | $20.1M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 8.0% |
| 净利率 | -29.5% | 6.3% |
| 营收同比 | -5.9% | 11.4% |
| 净利润同比 | -62.2% | 147.3% |
| 每股收益（稀释后） | $-0.40 | $1.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $319.3M | ||
| Q3 25 | $458.6M | $326.6M | ||
| Q2 25 | $178.5M | $316.3M | ||
| Q1 25 | $166.8M | $301.4M | ||
| Q4 24 | $212.5M | $286.7M | ||
| Q3 24 | $196.8M | $295.3M | ||
| Q2 24 | $199.7M | $269.8M | ||
| Q1 24 | $172.3M | $268.2M |
| Q4 25 | $-59.0M | $20.1M | ||
| Q3 25 | $215.7M | $28.3M | ||
| Q2 25 | $-42.2M | $28.9M | ||
| Q1 25 | $-92.2M | $21.9M | ||
| Q4 24 | $-36.4M | $8.1M | ||
| Q3 24 | $-57.4M | $25.9M | ||
| Q2 24 | $-37.7M | $16.6M | ||
| Q1 24 | $-66.4M | $20.1M |
| Q4 25 | -25.6% | 8.0% | ||
| Q3 25 | 48.7% | 11.1% | ||
| Q2 25 | -18.6% | 11.6% | ||
| Q1 25 | -50.0% | 9.4% | ||
| Q4 24 | -12.3% | 3.5% | ||
| Q3 24 | -24.0% | 11.1% | ||
| Q2 24 | -14.7% | 7.9% | ||
| Q1 24 | -36.0% | 9.5% |
| Q4 25 | -29.5% | 6.3% | ||
| Q3 25 | 47.0% | 8.7% | ||
| Q2 25 | -23.6% | 9.1% | ||
| Q1 25 | -55.3% | 7.3% | ||
| Q4 24 | -17.1% | 2.8% | ||
| Q3 24 | -29.2% | 8.8% | ||
| Q2 24 | -18.9% | 6.2% | ||
| Q1 24 | -38.5% | 7.5% |
| Q4 25 | $-0.40 | $1.36 | ||
| Q3 25 | $1.67 | $1.91 | ||
| Q2 25 | $-0.33 | $1.95 | ||
| Q1 25 | $-0.74 | $1.48 | ||
| Q4 24 | $-0.30 | $0.56 | ||
| Q3 24 | $-0.46 | $1.73 | ||
| Q2 24 | $-0.30 | $1.13 | ||
| Q1 24 | $-0.54 | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $73.9M |
| 总债务越低越好 | — | $50.0M |
| 股东权益账面价值 | $370.1M | $892.3M |
| 总资产 | $1.1B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $73.9M | ||
| Q3 25 | $479.2M | $56.2M | ||
| Q2 25 | $370.0M | $49.4M | ||
| Q1 25 | $358.4M | $64.7M | ||
| Q4 24 | $411.3M | $59.0M | ||
| Q3 24 | $396.9M | $82.3M | ||
| Q2 24 | $360.1M | $44.6M | ||
| Q1 24 | $325.9M | $30.8M |
| Q4 25 | — | $50.0M | ||
| Q3 25 | — | $30.0M | ||
| Q2 25 | — | $30.0M | ||
| Q1 25 | — | $30.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $892.3M | ||
| Q3 25 | $401.2M | $899.6M | ||
| Q2 25 | $156.3M | $873.3M | ||
| Q1 25 | $164.2M | $850.7M | ||
| Q4 24 | $228.5M | $828.5M | ||
| Q3 24 | $237.1M | $851.4M | ||
| Q2 24 | $264.3M | $810.2M | ||
| Q1 24 | $266.7M | $807.1M |
| Q4 25 | $1.1B | $2.5B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $821.4M | $2.4B | ||
| Q1 25 | $807.3M | $2.3B | ||
| Q4 24 | $885.1M | $2.3B | ||
| Q3 24 | $901.9M | $2.3B | ||
| Q2 24 | $904.5M | $2.2B | ||
| Q1 24 | $831.9M | $2.1B |
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.03× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $194.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $192.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 60.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 9.67× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $194.5M | ||
| Q3 25 | $108.5M | $85.5M | ||
| Q2 25 | $4.4M | $32.3M | ||
| Q1 25 | $-53.4M | $3.2M | ||
| Q4 24 | $19.4M | $128.7M | ||
| Q3 24 | $34.1M | $73.8M | ||
| Q2 24 | $-8.3M | $25.6M | ||
| Q1 24 | $-133.0M | $-21.1M |
| Q4 25 | $-14.3M | $192.0M | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | $32.3M | ||
| Q1 25 | $-53.4M | $2.8M | ||
| Q4 24 | $19.3M | $124.3M | ||
| Q3 24 | — | $73.2M | ||
| Q2 24 | $-8.4M | $25.0M | ||
| Q1 24 | $-133.3M | $-24.2M |
| Q4 25 | -7.1% | 60.1% | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | 10.2% | ||
| Q1 25 | -32.0% | 0.9% | ||
| Q4 24 | 9.1% | 43.4% | ||
| Q3 24 | — | 24.8% | ||
| Q2 24 | -4.2% | 9.3% | ||
| Q1 24 | -77.3% | -9.0% |
| Q4 25 | 0.1% | 0.8% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 1.5% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 1.1% |
| Q4 25 | — | 9.67× | ||
| Q3 25 | 0.50× | 3.02× | ||
| Q2 25 | — | 1.12× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 15.83× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 1.54× | ||
| Q1 24 | — | -1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SAFT
暂无分部数据
